Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing oral antiviral therapies to address unmet medical needs in viral diseases, including hepatitis C and COVID-19. The company leverages its expertise in antiviral drug development, medicinal chemistry, biology, biochemistry, and virology to create innovative treatments with the potential to transform patient care.
Industries
Nr. of Employees
medium (51-250)
Products
Oral combination regimen of a nucleotide analog polymerase inhibitor and an NS5A inhibitor for hepatitis C
An oral two-drug regimen combining a nucleotide analog polymerase inhibitor and an NS5A inhibitor designed as a pan-genotypic, once-daily treatment for hepatitis C virus (HCV); demonstrated high sustained virologic response in Phase 2 and advanced to global Phase 3 development.
Oral combination regimen of a nucleotide analog polymerase inhibitor and an NS5A inhibitor for hepatitis C
An oral two-drug regimen combining a nucleotide analog polymerase inhibitor and an NS5A inhibitor designed as a pan-genotypic, once-daily treatment for hepatitis C virus (HCV); demonstrated high sustained virologic response in Phase 2 and advanced to global Phase 3 development.
Services
Antiviral drug discovery and development
End-to-end internal capabilities for discovering, optimizing and advancing oral small-molecule antivirals, including medicinal chemistry, preclinical studies, CMC and clinical development.
Partnerships for development and commercialization
Strategic collaborations and licensing arrangements to develop, distribute and commercialize investigational antiviral therapies.
Antiviral drug discovery and development
End-to-end internal capabilities for discovering, optimizing and advancing oral small-molecule antivirals, including medicinal chemistry, preclinical studies, CMC and clinical development.
Partnerships for development and commercialization
Strategic collaborations and licensing arrangements to develop, distribute and commercialize investigational antiviral therapies.
Expertise Areas
- Clinical trial management (Phase 1–3)
- Antiviral drug discovery and development
- Medicinal chemistry of nucleoside/nucleotide prodrugs
- Purine nucleotide prodrug development
Key Technologies
- Purine nucleotide prodrug chemistry
- Nucleoside/nucleotide analogs
- Viral RNA-dependent RNA polymerase inhibition
- In vitro replicon assays